Buy Cilostazol Powder Antiplatelet Aggregation Drug Online CAS 73963-72-1
Cilostazol Specification
Product Name: Cilostazol
CAS: 73963-72-1
Standard: Enterprise Standard
Level: Medical grade
Content: 99%
Appearance: white powder
Packing: 25KG/ cardboard drum detachable
Physical and chemical properties: White or off-white crystalline powder; odorless. This product is soluble in glacial acetic acid or chloroform, dissolved in dimethylformamide, slightly soluble in methanol or absolute ethanol, in water, 0.1mol/L hydrochloric acid solution or 0.1mol/L sodium hydroxide solution. Almost insoluble.
Category: Pharmaceutical raw materials
Area: Antiplatelet aggregation drugs
Deferred product: cilostazol capsule
Application: 1. Cilostazol has vasodilating action and anti-platelet function, and is used for the treatment of chronic arterial occlusive disease caused by atherosclerosis, arteritis, occlusive thromboangiitis and diabetes. 2. Cilostazol can improve chronic ulcers, pain, coldness and intermittent claudication caused by limb ischemia, and can be used for angioplasty, vascular grafting, and complementary treatment after sympathectomy to help relieve symptoms. Improve circulation and inhibit thrombosis in transplanted blood vessels.
Dosage: 50 ~ 100mg each time, 2 times a day, young patients can increase the dose according to the symptoms if necessary.
What is Cilostazol?
Cilostazol is a quinolinone-derivative medication used in the alleviation of the symptoms of intermittent claudication in individuals with peripheral vascular disease.
Cilostazol is a phosphodiesterase 3 inhibitor with therapeutic focus on cyclic adenosine monophosphate (cAMP). It inhibits platelet aggregation and widens arteries (direct arterial vasodilator). Its main effects are dilation of the arteries supplying blood to the legs and decreasing platelet coagulation.
Cilostazol Certificate of Analysis
| Product name |
Cilostazol |
| CAS No. |
73963-72-1 |
Outer Packing |
1KG Aluminum foil bag |
| Production date |
2015.09.01 |
Shelf life |
2017.08.31 |
| Standard adopted |
Enterprise standard |
| Items of analysis |
Specification |
Results |
| Appearance |
White crystalline powder |
Confirms |
| Melting point |
158-162℃ |
158-161℃ |
| Dry weight loss |
≤0.3% |
≤0.27% |
| Ash content |
≤0.1% |
0.09% |
| Heavy metals |
≤10ppm |
10ppm |
| Methanol |
≤0.1% |
0.08% |
| Chloride |
≤0.02% |
0.015% |
| Main impurity |
≤0.2% |
0.187% |
| Total impurity |
≤0.5% |
≤0.5% |
| Purity（HPLC） |
≥99% |
99.5% |
| Conclusion |
Qualified |
